Idioma:

Large Scale Manufacturing of TXU(Anti-CD7)-Pokeweed Antiviral Protein (PAP) Immunoconjugate for Clinical Trials

Myers, Dorothea E. ; Jun, Xiao ; Clementson, Dina ; Donelson, Randy ; Sicheneder, Andrew ; Hoffman, Nathan ; Bell, Kim ; Sarquis, Mireille ; Langlie, Mridula-Chandan ; Turner, Nilgun ; Uckun, Fatih M.

Leukemia & lymphoma, 1997, Vol.27 (3-4), p.275-302 [Periódico revisado por pares]

United States: Informa UK Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Large Scale Manufacturing of TXU(Anti-CD7)-Pokeweed Antiviral Protein (PAP) Immunoconjugate for Clinical Trials
Autor: Myers, Dorothea E. ; Jun, Xiao ; Clementson, Dina ; Donelson, Randy ; Sicheneder, Andrew ; Hoffman, Nathan ; Bell, Kim ; Sarquis, Mireille ; Langlie, Mridula-Chandan ; Turner, Nilgun ; Uckun, Fatih M.
Assuntos: Antibodies, Monoclonal ; Antigens, CD7 - immunology ; Antineoplastic Agents, Phytogenic - therapeutic use ; clinical trials ; Clinical Trials as Topic ; Humans ; Immunotoxins - isolation & purification ; Immunotoxins - therapeutic use ; Leukemia-Lymphoma, Adult T-Cell - drug therapy ; Manufacturing of immunoconjugate ; N-Glycosyl Hydrolases ; Plant Proteins - immunology ; Pokeweed anti-viral protein (PAP) ; Quality Control ; Ribosome Inactivating Proteins, Type 1 ; TXU (anti-CD7)
É parte de: Leukemia & lymphoma, 1997, Vol.27 (3-4), p.275-302
Descrição: We have conjugated the murine monoclonal anti-CD7 antibody TXU to the plant hemitoxin pokeweed antiviral protein (PAP) to construct an effective immunotoxin against CD7 antigen positive hematologic malignancies. The scaled-up production and purification of TXU antibody, PAP toxin, and TXU-PAP immunotoxin permitted the manufacturing of a highly purified clinical-grade TXU-PAP preparation. In clonogenic assays, TXU-PAP elicited selective and potent cytotoxicity against CD7 antigen positive human leukemia cells and killed primary clonogenic leukemic cells from T-lineage acute lymphoblastic leukemia (ALL) patients. To our knowledge, this pre-IND work represents the first effort of producing a clinical-grade PAP immunotoxin for treatment of T-lineage ALL. Since the CD7 antigen is also expressed on AML cells, TXU-PAP could also be useful for the treatment of CD7 positive acute myeloid leukemia (AML) patients.
Editor: United States: Informa UK Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 2

Realização: Logos de Redes Sociais:

Large Scale Manufacturing of TXU(Anti-CD7)-Pokeweed Antiviral Protein (PAP) Immunoconjugate for Clinical Trials

Myers, Dorothea E. ; Jun, Xiao ; Clementson, Dina ; Donelson, Randy ; Sicheneder, Andrew ; Hoffman, Nathan ; Bell, Kim ; Sarquis, Mireille ; Langlie, Mridula-Chandan ; Turner, Nilgun ; Uckun, Fatih M.

United States: Informa UK Ltd

Buscando em bases de dados remotas. Favor aguardar.